Background
Methods
Patient cohort study
Tissue microarray (TMA) and Immunohistochemistry (IHC)
TMA scoring
Statistical analysis
Results
Study of the patient cohort
Prognostic factors | Cases (%) | Univariate Pa
| Multivariate | |
---|---|---|---|---|
HR (95% CI) | Pb
| |||
Age (years) | 0.281 | 0.495 | ||
≤ 57 (median) | 57(50.4) | 1.000 | ||
> 57 (median) | 56(49.6) | 1.010(0.982–1.037) | ||
FIGO Stage |
0.002
|
0.047
| ||
Early(I + II) | 17(15.0) | 1.000 | ||
Late(III + IV) | 96(85.0) | 3.241(1.065–10.879) | ||
Residual tumor (cm) |
0.042
| 0.543 | ||
≤ 1 | 104(92.0) | 1.000 | ||
> 1 | 9(8.0) | 1.300 (0.558–3.027) | ||
Ascites | 0.085 | 0.690 | ||
No | 11(9.7) | 1.000 | ||
Yes | 102(90.3) | 1.280(0.380–4.311) | ||
Endometriosis | 0.140 | 0.568 | ||
No | 101(89.4) | 1.000 | ||
Yes | 12(10.6) | 1.245(0.586–2.647) | ||
Chemotherapeutic response |
0.000
|
0.000
| ||
Platinum sensitive | 77(72.0) | 1.000 | ||
Platinum resistant | 30(28.0) | 3.573(2.056–6.210) |
Prognostic factors | Cases (%) | Univariate | Multivariate | |
---|---|---|---|---|
96(100) | Pc
| HR (95% CI) | Pd
| |
Age (years) | 0.524 | 0.292 | ||
≤ 54 (median) | 50(52.1) | 1.000 | ||
> 54 (median) | 46(47.9) | 0.980(0.944–1.017) | ||
FIGO Stage |
0.000
|
0.007
| ||
Early(I + II) | 64(66.7) | 1.000 | ||
Late(III + IV) | 32(33.3) | 4.660(1.533–14.167) | ||
Residual tumor (cm) | 0.115 | 0.541 | ||
≤ 1 | 93(96.9) | 1.000 | ||
> 1 | 3(3.1) | 1.690 (0.314–9.080) | ||
Ascites |
0.005
| 0.338 | ||
No | 53(55.2) | 1.000 | ||
Yes | 43(44.8) | 1.613(0.606–4.290) | ||
Endometriosis | 0.121 | 0.568 | ||
No | 78(81.3) | 1.000 | ||
Yes | 18(18.7) | 0.647(0.144–2.894) | ||
Chemotherapeutic response |
0.000
|
0.003
| ||
Platinum sensitive | 64(72.7) | 1.000 | ||
Platinum resistant | 24(27.3) | 7.230(1.992–26.237) |
Ovarian CCC patients showed different expression map of drug-based molecular biomarkers from HGSC patients
Molecular biomarkers | High-grade serous carcinoma | Clear cell carcinoma |
P
e value | ||||
---|---|---|---|---|---|---|---|
Cases (%) | P(OS) | P(PFS) | Cases (%) | P(OS) | P(PFS) | ||
EGFR | 113(100) |
0.017
|
0.042
| 92(100) |
0.012
| 0.267 | 0.195 |
Negative | 82(72.6) | 59(64.1) | |||||
Positive | 31(27.4) | 33(35.9) | |||||
HER2 | 113(100) | 0.938 | 0.475 | 95(100) |
0.001
| 0.200 |
0.006
|
Negative | 110(97.3) | 83(87.4) | |||||
Positive | 3(2.7) | 12(12.6) | |||||
PTEN | 113(100) | 0.323 | 0.397 | 93(100) | 0.160 | 0.061 | 0.716 |
Negative | 99(87.6) | 83(89.2) | |||||
Positive | 14(12.4) | 10(10.8) | |||||
AURKA | 113(100) |
0.006
| 0.382 | 95(100) |
0.022
|
0.035
| 0.582 |
Negative | 72(63.7) | 57(60.0) | |||||
Positive | 41(36.3) | 38(40.0) | |||||
BRCA1 | 113(100) |
0.017
|
0.032
| 92(100) | 0.823 | 0.424 |
0.007
|
Negative | 82(72.6) | 50(54.3) | |||||
Positive | 31(27.4) | 42(45.7) | |||||
BRCA2 | 113(100) | 0.743 | 0.500 | 94(100) | 0.466 | 0.929 | 0.054 |
Negative | 101(89.4) | 75(79.8) | |||||
Positive | 12(10.6) | 19(20.2) | |||||
PD-L1 | 113(100) |
0.037
| 0.159 | 95(100) | 0.773 | 0.425 | 0.064 |
Negative | 99(88.4) | 75(78.9) | |||||
Positive | 13(11.6) | 20 (21.1) |
High-grade serous carcinoma | Clear cell carcinoma | |||
---|---|---|---|---|
Factors | Hazard Ratio (95% CI) | HGSC P | Hazard Ratio (95% CI) | CCC P |
Stage | ||||
Early(I + II) | 1.000 | 1.000 | ||
Late(III + IV) | 3.320(0.965–11.427) | 0.057 | 9.703(2.588–36.381) |
0.001
|
Residual tumor | ||||
< 1 cm | 1.000 | 1.000 | ||
> 1 cm | 1.367(0.560–3.339) | 0.492 | 1.400(0.244–8.032) | 0.706 |
Ascites | ||||
No | 1.000 | 1.000 | ||
Yes | 0.994(0.293–3.373) | 0.993 | 2.587(0.848–7.890) | 0.095 |
Chemotherapeutic response | ||||
Sensitive | 1.000 | 1.000 | ||
Resistant | 3.803(2.170–6.664) |
0.000
| 3.562(1.063–11.936) |
0.040
|
EGFR | ||||
Negative | 1.000 | 1.000 | ||
Positive | 1.244(0.653–2.370) | 0.507 | 0.044(0.003–0628) |
0.021
|
HER2 | ||||
Negative | 1.000 | 1.000 | ||
Positive | 1.277(0.299–5.456) | 0.741 | 7.948(1.745–36.208) |
0.007
|
PTEN | ||||
Negative | 1.000 | 1.000 | ||
Positive | 0.696(0.257–1.880) | 0.474 | 4.475(0.825–24.274) | 0.082 |
AURKA | ||||
Negative | 1.000 | 1.000 | ||
Positive | 2.082(1.162–3.730) |
0.014
| 1.763(0.616–5.044) | 0.291 |
BRCA1 | ||||
Negative | 1.000 | 1.000 | ||
Positive | 0.433(0.211–0.885) |
0.022
| 1.934(0.653–5.738) | 0.235 |
BRCA2 | ||||
Negative | 1.000 | 1.000 | ||
Positive | 1.671(0.755–3.701) | 0.206 | 1.258(0.352–4.493) | 0.723 |
PD-L1 | ||||
Negative | 1.000 | 1.000 | ||
Positive | 0.520(0.182–1.487) | 0.222 | 1.157(0.387–3.456) | 0.794 |
Expression of drug-based molecular biomarkers in ovarian CCC exhibited various relationships to clinicopathological factors
Molecular biomarkers | HGSC | CCC | ||||
---|---|---|---|---|---|---|
Platinum sensitive (%) |
aPlatinum resistant (%) | HGSCP | Platinum sensitive (%) |
aPlatinum resistant (%) | CCC P | |
EGFR | 0.365 | 0.129 | ||||
Negative | 58(75.3) | 20(66.7) | 36(58.1) | 17(77.3) | ||
Positive | 19(24.7) | 10(33.3) | 26(41.9) | 5(22.7) | ||
HER2 | 1.000 | 0.725 | ||||
Negative | 75(97.4) | 29(96.7) | 56(87.5) | 19(82.6) | ||
Positive | 2(2.6) | 1(3.3) | 8(12.5) | 4(17.4) | ||
PTEN | 0.530 | 0.679 | ||||
Negative | 68(88.3) | 25(83.3) | 58(92.1) | 21(87.5) | ||
Positive | 9(11.7) | 5(16.7) | 5(7.9) | 3(12.5) | ||
AURKA | 0.505 |
0.042
| ||||
Negative | 49(63.6) | 17(56.7) | 42(65.6) | 10(41.7) | ||
Positive | 28(36.3) | 13(43.3) | 22(34.4) | 14(58.3) | ||
BRCA1 | 0.584 | 0.848 | ||||
Negative | 55(71.4) | 23(76.7) | 35(56.5) | 13(54.2) | ||
Positive | 22(28.6) | 7(23.3) | 27(43.5) | 11(45.8) | ||
BRCA2 | 1.000 | 0.542 | ||||
Negative | 68(88.3) | 27(90.0) | 50(80.6) | 21(87.5) | ||
Positive | 9(11.7) | 3(10.0) | 12(19.4) | 3(12.5) | ||
PD-L1 | 0.502 |
0.028
| ||||
Negative | 66(86.8) | 28(93.3) | 56(87.5) | 15(65.2) | ||
Positive | 10(13.2) | 2(6.7) | 8(12.5) | 8(34.8) |